- Home
- HPE vs BIIB Comparison
HPE vs BIIB Comparison
Compare HPE & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPE
- BIIB
- Stock Information
- Founded
- HPE 1939
- BIIB 1978
- Country
- HPE United States
- BIIB United States
- Employees
- HPE N/A
- BIIB N/A
- Industry
- HPE Retail: Computer Software & Peripheral Equipment
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- HPE Technology
- BIIB Health Care
- Exchange
- HPE Nasdaq
- BIIB Nasdaq
- Market Cap
- HPE 26.7B
- BIIB 25.1B
- IPO Year
- HPE N/A
- BIIB 1991
- Fundamental
- Price
- HPE $22.02
- BIIB $149.90
- Analyst Decision
- HPE Buy
- BIIB Buy
- Analyst Count
- HPE 14
- BIIB 26
- Target Price
- HPE $24.00
- BIIB $248.00
- AVG Volume (30 Days)
- HPE 16.9M
- BIIB 1.5M
- Earning Date
- HPE 12-05-2024
- BIIB 02-11-2025
- Dividend Yield
- HPE 2.36%
- BIIB N/A
- EPS Growth
- HPE 25.32
- BIIB 10.05
- EPS
- HPE 1.93
- BIIB 11.06
- Revenue
- HPE $30,127,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- HPE $8.55
- BIIB N/A
- Revenue Next Year
- HPE $5.18
- BIIB N/A
- P/E Ratio
- HPE $11.42
- BIIB $13.55
- Revenue Growth
- HPE 3.40
- BIIB N/A
- 52 Week Low
- HPE $14.47
- BIIB $145.07
- 52 Week High
- HPE $24.24
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- HPE 54.19
- BIIB 35.04
- Support Level
- HPE $20.60
- BIIB $145.07
- Resistance Level
- HPE $22.17
- BIIB $149.92
- Average True Range (ATR)
- HPE 0.74
- BIIB 3.71
- MACD
- HPE -0.04
- BIIB 0.26
- Stochastic Oscillator
- HPE 39.70
- BIIB 30.65
About HPE Hewlett Packard Enterprise Company
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment; it also has a high-performance computing business. HPE's stated goal is to be a complete edge-to-cloud company. Its portfolio enables hybrid clouds and hyperconverged infrastructure. It uses a primarily outsourced manufacturing model and employs 60,000 people worldwide.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.